LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central nervous system (CNS) of children with CLN2 disease FDA designations underscore the potential of LTS-101 to address a high unmet medical need PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company…
Read More
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announced a major expansion of its artificial intelligence and machine learning (AI/ML) strategy and the addition of two world-class scientific advisors: Pranam Chatterjee, PhD (University of Pennsylvania) and Philip M. Kim, PhD (University…
Read More
Latus Bio Strengthens Executive Team with Appointments of Ainslie Little as COO and Katie Hewitt as interim CBO BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company driving advances in AAV gene therapy, announces the appointments of Ainslie Little, PhD, as COO and Katie Hewitt, as interim CBO. “These appointments reflect…
Read More